LONG-TERM SURVIVAL OF UNRESECTABLE HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH ATEZOLIZUMAB/BEVACIZUMAB OR TREMELIMUMAB PLUS DURVALUMAB: A RECONSTRUCTED INDIVIDUAL PARTICIPANT DATA META-ANALYSIS

Teng Kiat Koh  ¹     James Ho  ¹     Alfred Kow  ¹     David Pinato  ²     Arndt Vogel  ³     Mark Muthiah  ³     Daniel Huang  ^3    
1 National University Hospital, Singapore, Singapore
² Imperial College London, London, United Kingdom
³ Medizin. Hochschule Hannover, Hannover, Germany

Topic
Digestive Oncology, Hepatobiliary, Pancreas

Session
Hepatobiliary and pancreatic cancer: Basic meets clinical practice

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)